This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Multidetector Computed Tomography (MDCT) Tailored Protocol

This study has been completed.
Information provided by (Responsible Party):
Bracco Diagnostics, Inc Identifier:
First received: November 20, 2012
Last updated: September 27, 2013
Last verified: September 2013
Collection of data from different sites regardless of whether they use standard or tailored protocols for the application of high concentration iodinated contrast agents to assess if the individually patient-adapted protocols result in a similar diagnostic image quality.

Patients Undergoing Contrast Enhanced Multidetector Computed Tomography of the Chest, Abdomen, Liver or Aorta for Any Diagnostic Cause

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Multicenter, Multinational, Randomized Study of Standard vs. Patient-Adapted Protocols in Multidetector Computed Tomography (MDCT) of the Chest, Abdomen, Liver or Aorta

Resource links provided by NLM:

Further study details as provided by Bracco Diagnostics, Inc:

Primary Outcome Measures:
  • Diagnostic Quality [ Time Frame: Immediately after the single injection of contrast agent ]
    Images are to be assessed according to the following scale: 0=Uninterpretable (Image quality severely affected by motion artifacts or technical reasons; need to repeat the examination); 1=Insufficient (Impaired image quality precludes adequate diagnostic assessment because of severe image noise or insufficient contrast enhancement; need to repeat the examination); 2=Adequate (Image quality in terms of noise and contrast enhancement does not interfere with sufficient diagnostic assessment; delineation of small structures may be suboptimal); or 3=Good (Absent or minimal image noise and good contrast enhancement allow adequate diagnostic assessment with clear delineation of even small structures).

Enrollment: 1493
Study Start Date: October 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Detailed Description:
To record technical information and compare image quality regarding routine MDCT procedures with contrast administration using a tailored contrast injection and radiation dose protocol. The hypotheses are that the tailored protocols lead to a lower applied mean radiation dose compared to the use of standard protocols and will provide a more standardized contrast dose per patient size without impairing diagnostic quality.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients undergoing MDCT of the abdomen, liver, chest or aorta and receiving high iodinated contrast agents

Inclusion Criteria:

  • At least 18 years of age
  • Scheduled to undergo contrast enhanced MDCT of the abdomen, liver, aorta, or chest
  • Provides written informed consent

Exclusion Criteria:

  • Previously enrolled and completed the study
  • Known allergy to iodinated contrast media
  • Pregnancy or lactation
  • Clinically unsuitable for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01737333

United States, North Carolina
Department of Radiology Carolinas Medical Center
Charlotte, North Carolina, United States, 28203
Oepedale Niguarda
Milan, Italy, 20162
Sponsors and Collaborators
Bracco Diagnostics, Inc
Study Director: Martin Krix, M.D. Bracco Diagnostics, Inc
  More Information

Responsible Party: Bracco Diagnostics, Inc Identifier: NCT01737333     History of Changes
Other Study ID Numbers: IOPM-101
Study First Received: November 20, 2012
Last Updated: September 27, 2013 processed this record on September 18, 2017